Results 151 to 160 of about 23,789,882 (297)

Due Process and Denaturalization

open access: yes, 2019
May 13, 2019 Due Process and Denaturalization In this Faculty View at CWRU, Professor Cassandra Robertson discusses how policies restricting immigration and citizenship play a significant role in the current political environment, due process and ...
Robertson, Cassandra Burke
core  

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

From Bureaucracy to Black Box: Revolutionizing Natural Justice and Due Process in Administrative Law

open access: yesActa Universitatis Danubius: Administratio
Natural justice, rooted in English common law, embodies fairness in procedural justice and is foundational to Administrative law (Aslam, 2020). The growing use of Artificial Intelligence (AI) (Rosenberg, 2023) in administrative decision-making raises ...
Junaid Sattar Butt
doaj  

Flow Enabled Target Capture Halbach‐based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

open access: yesMolecular Oncology, EarlyView.
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens   +6 more
wiley   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

open access: yesMolecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy